IXICO Present at CTAD 2016
IXICO will be presenting at the 9th Clinical Trials on Alzheimer's Disease (CTAD) conference this year, in San Diego from 8-10 December 2016.
Derek Hill, CEO of IXICO will be joined by the Science and Business Development teams at the event which will see the following oral and poster presentations:
Individualized trajectories in pre-symptomatic and prodromal AD: subject-specific Jack curves estimated using statistical models.
Authorship: Robin Wolz, PhD, Adam J. Schwarz, PhD , Ricardo Guerrero, PhD, Derek Hill, PhD
Presenter: Robin Wolz, PhD, Director Translational Science at IXICO
Date: Friday 9th December 2016
Time: 4.30 p.m (PST)
Location: Marina Ballroom DEF - Level 3
Digital Biomarkers for Clinical Trial Use in Pre-symptomatic to Symptomatic Alzheimer’s Disease and Related Dementias – Building the Regulatory Science Roadmap
Authorship: Stephen P. Arnerić, PhD, Daniel R. Karlin, MD, Maurizio F. Facheris, MD, Jesse M. Cedarbaum, MD, Mark Forrest Gordon, MD, Enrique Avilés, Derek L. Hill, PhD, Lynn D. Hudson, PhD, Volker D. Kern, PhD, Klaus Romero, MS, MD, Jane Rhodes, MBA, PhD, George Vrandenburg, Penny A. Dacks, PhD, Jeffrey A. Kaye, MD
Date: Friday 9th December 2016
Session: P2-11; THEME 5: Clinical trials: cognitive and functional endpoints
Location: San Diego Ballroom - Lobby Level
IXICO has been investing in broadening our range of expertise and capabilities beyond MR and PET imaging into the field of digital health including wearable biosensors and companion digital technologies. At the event we will discussing the following:
Assessa® - Disease modelling for patient selection and stratification
IXICO’s Assessa® digital platform combines clinical, demographic and biomarker measurements into a data driven prognostic model to predict the likely disease trajectory for individual patients. We are validating this technology to enrich patient populations enrolled in clinical trials and as a clinical decision support platform to support more informative patient management and treatment decisions in the clinic.
Collection of continuous passive data from patients could be extremely valuable in both the development of new therapies and the monitoring and management of patients in the clinic.
IXICO have integrated wearable biosensors into its GCP compliance digital technology platform and are collaborating to collect wearable biosensor data from patients and to validate digital biomarkers and the next generation of outcome measures.
Automated Image Analysis
Our automated image processing algorithms characterize and quantify AD biomarkers including the assessment from brain atrophy (volumetric MRI), vascular load (FLAIR MRI) amyloid and tau load (PET), brain glucose metabolism (FDG-PET), and markers brain connectivity/function (rs-fMRI, DTI and ASL).
ARIA radiological reads
IXICO work with leading neuroradiology experts in the field for ARIA reads and our TrialTracker platform provides a GCP compliant Image Data Management infrastructure for rapid and scalable central radiological reading of MRI data.
The aim of CTAD is to bring together worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
If you are attending and would like to take this opportunity to arrange a meeting with the team please contact DAVID.STRINATI@IXICO.COM.